Skip to main content

Table 3 Self-administered SCIg and clinic-administered IVIg health care resource use and costs presented overall, and during the first and subsequent years(s) of treatment among the total patient population, and the adult and pediatric cohorts

From: Economic impact of self-administered subcutaneous versus clinic-administered intravenous immunoglobulin G therapy in Alberta, Canada: a population-based cohort study

 

Total patient population

Adult cohort

Pediatric cohort

Self-administered SCIg

Clinic-administered IVIg

Increment: SCIg minus IVIg

Self-administered SCIg

Clinic-administered IVIg

Increment: SCIg minus IVIg

Self- administered SCIg

Clinic-administered IVIg

Increment:

SCIg minus IVIg

Cost ($CDN) per patient-year, mean (95% CI); n or p-value

Overall

Total

$817 (723,912); n = 684

$6,204 (6100,6308); n = 7,584

-$5,386 (-5039,-5734); p < 0.001

$782 (696,868); n = 638

$6,714 (6586,6841); n = 5,852

-$5,931 (-5543,-6319); p < 0.001

$1,305 (549,2060); n = 46

$4,482 (4369,4595); n = 1,732

-$3,177 (-2473,-3882); p < 0.001

Preparation and dispensation

$237 (221,254)

$246 (242,250)

 

$235 (219,252)

$272 (267,277)

 

$261 (160,363)

$159 (154,163)

 

Training (SCIg) or visits (IVIg)

$323 (320,326)

$5,958 (5857,6058)

 

$320 (317,323)

$6,441 (6318,6564)

 

$363 (349,377)

$4,323 (4214,4432)

 

First-year

Total

$573 (556,590); n = 684

$6,319 (6213,6424); n = 7,584

-$5,746 (-5639,-5852); p < 0.001

$569 (553,585);  n = 638

$6,853 (6723,6982); n = 5,852

-$6,284 (-6153,-6414);  p < 0.001

$628 (523,732);  n = 46

$4,514 (4401,4628); n = 1,732

-$3,887 (-3734,-4039);  p < 0.001

Preparation and dispensation

$250 (234,266)

$250 (246,254)

 

$249 (233,265)

$277 (272,282)

 

$264 (163,366)

$159 (154,163)

 

Training (SCIg) or visits (IVIg)

$323 (320,326)

$6,068 (5967,6170)

 

$320 (317,323)

$6,575 (6451,6700)

 

$363 (349,377)

$4,355 (4246,4465)

 

Subsequent year(s)

Total

$250 (185,314);  n = 406

$4,045 (3589,4501); n = 1,988

-$3,796 (-3335,-4256); p < 0.001

$254 (186,322);  n = 381

$4,267 (3733,4801); n = 1,692

-$4,013 (-3475,-4552)

p < 0.001

$186 (138,233); n n = 25

$2,776 (2589,2963); n = 296

-$2,591 (-2386, -2783); p < 0.001

Preparation and dispensation

$250 (185,314)

$160 (142,177)

 

$254 (186,322)

$170 (150,191)

 

$186 (138,233)

$101 (94,107)

 

Training (SCIg) or visits (IVIg)

N/A

$3,885 (3,447,4,324)

 

N/A

$4,097 (3583,4610)

 

N/A

$2,675 (2495,2856)

 
  1. Univariate generalized linear model regression with gamma distribution and log link was used to compare cost differences between self-administered SCIg and clinic-administered IVIg; two-sided p-values < 0.05 were considered statistically significant
  2. IVIg intravenous immunoglobulin G; SCIg subcutaneous immunoglobulin G